GleamWall
中文EN

LYEL Lyell Immunopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1806952 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-63.4%
TTM net income YoY21.6%
TTM EPS YoY44.6%
Revenue 3-yr CAGR-93.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,783,580.0%
Net margin-1,701,066.7%
FCF margin-933,100.0%
EBITDA margin-1,723,546.7%

Returns

ROE-97.8%
ROA-74.8%
ROIC (approx.)-138.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets29.6%
Debt / equity0.00x
Current ratio4.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue4,766.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3,000$4,000$2,000$6,000$15,000$8,000$7,000$11,000
R&D expense$40.90M$39.52M$36.60M$52.20M$28.17M$34.86M$43.45M$48.67M
SG&A expense$9.30M$9.58M$9.55M$10.62M$10.69M$9.79M$14.05M$14.52M
Operating income-$48.30M-$47.34M-$44.26M-$127.64M-$37.25M-$47.14M-$57.37M-$201.15M
Net income-$45.53M-$44.76M-$24.15M-$140.72M-$38.85M-$42.68M-$52.20M-$191.94M
EBITDA-$46.24M-$45.12M-$41.93M-$125.25M-$34.69M-$44.01M-$53.93M-$196.12M
EPS (basic)-1.86-1.92-1.10—-2.13-2.89-3.54—
EPS (diluted)-1.86-1.92-1.10—-2.13-2.89-3.54—
Weighted avg. shares (diluted)24.44M23.36M21.88M—18.27M14.79M14.76M—
Balance sheet
Cash & equivalents$92.05M$72.98M$90.77M$60.18M$123.58M$98.80M$120.33M$107.29M
Short-term investments$85.05M$131.12M$163.25M$187.04M$196.05M$177.99M$180.85M$264.93M
Current assets$186.21M$213.54M$267.30M$260.94M$328.20M$282.21M$309.18M$379.59M
PP&E, net$28.53M$30.51M$32.72M$34.77M$36.72M$39.12M$44.20M$48.20M
Total assets$273.85M$311.15M$350.63M$340.05M$407.96M$385.45M$429.80M$490.86M
Current liabilities$46.27M$39.87M$36.95M$49.41M$31.88M$36.90M$41.28M$53.79M
Total liabilities$81.13M$77.34M$76.96M$91.85M$78.84M$86.53M$93.28M$108.03M
Shareholders' equity$192.72M$233.81M$273.67M$248.20M$329.12M$298.92M$336.52M$382.82M
Shares outstanding24.58M23.40M23.33M21.25M19.29M14.83M295.28M14.74M
Cash flow statement
Operating cash flow-$34.57M-$33.92M-$38.51M-$32.25M-$28.58M-$34.46M-$54.74M-$47.24M
Capital expenditure$66,000$256,000$89,000$304,000$62,000$168,000$246,000$44,000
Free cash flow-$34.63M-$34.18M-$38.60M-$32.55M-$28.64M-$34.63M-$54.98M-$47.29M
Investing cash flow$53.59M$15.62M$17.38M-$31.36M$3.35M$12.65M$69.47M$53.51M
Financing cash flow$41,000$522,000$51.72M$222,000$50.00M$183,000$1,000$437,000
Depreciation & amortization$2.05M$2.22M$2.33M$2.40M$2.57M$3.13M$3.44M$5.03M
Stock-based compensation$4.51M$4.53M$4.29M$25.57M$5.23M$5.00M$6.02M$8.08M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.